摘要
目的观察复方861胶囊(CPD861)对慢性肝病患者的抗肝纤维化效果。方法慢性肝病肝纤维化患者67例采用随机、双盲、安慰剂对照的方法,治疗组34例,服用复方861胶囊,安慰剂组33例服用安慰剂胶囊共24周,观察治疗前后患者血清肝纤维化指标以及肝病理组织学的变化。结果治疗组和安慰剂组治疗后血清TIMP1分别为(136.7±56.8)μg/L和(172.6±77.4)μg/L(P<0.05);MMP9分别为(82.6±67.7)μg/L和(119.6±72.6)μg/L(P<0.05);TIMP1/MMP1比值分别为(17.2±25.6)和(51.1±87.6)(P<0.05)。肝组织炎症计分分别为(10.1±6.3)和(14.6±6.1),纤维化计分分别为(8.2±3.8)和(11.1±6.7),病理图像分析胶原相对含量分别为(13.7±8.3)%和(17.9±9.7)%(P<0.05);肝纤维化总逆转率58.82%;安慰剂组24.24%,(P<0.05)。结论CPD861可以逆转慢性肝病肝纤维化、早期肝硬化。
Objective To further assess the clinical antiftbrotic efficacy of CPD861 on chronic hepatitis related fibrosis in a randomized,double blind and placeho controlled clinical trial. Methods Total 67 patients with chronic hepatitis related fibrosis were randomly allocated into CPD861 treatment group and placebo group for 24-week treatment. Serum fibrosis markers and liver biopsies were assessed before and after the trial. Results At the end of treatment, for CPD861 group and placebo group,serum TIMP1 was （ 136.7 ± 56.8 ） μg/L and （ 172.6 ± 77.4 ） μg/L （ P 〈 0.05 ） respectively ; MMP was （ 982.6 ± 67.7 ） μg/L and （ 119.6 ± 72.6 ） μg/L （ P 〈 0. 05 ） ; The ratio of TIMP1/ MMP1 was （ 17.2 ± 25.6 ） and （ 51.1 ± 87.6 ） （P 〈 0.05 ） ; Hepatic inflammatory score was （ 10. 1 ± 6.3 ） and （ 14.6 ± 6.1 ） ;fibrosis score was （ 8.2 ± 3.8 ） and （ 11. 1 ± 6.7 ） ; the relative content of collagen was （ 13.7 ± 8.3 ） % and （ 17.9 ± 9.7 ） % （ P 〈 0.05 ）. The reversal rate of fibrosis in CPD861 group was 58.82% while in placebo group it＇s 24.24% （ P 〈 0.05 ）. Conclusion CPD 861 could reverse liver fibrosis and early cirrhosis.
出处
《潍坊医学院学报》
2008年第1期53-55,共3页
Acta Academiae Medicinae Weifang
